Your Shopping Cart Is Empty
| Report Code: A04309 | Feb 2021 | Pages: 244 | ||
| Tables: 146 | Charts: 52 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Topical Pain Relief Market
Request Now !The global topical pain relief market size was valued at $8,864.0 million in 2019, and is projected to reach $12,219.7 million by 2027 at a CAGR of 5.2% from 2020 to 2027.
The COVID-19 outbreak is anticipated to impact the growth of the global topical pain relief market. The COVID-19 pandemic has stressed healthcare systems of the world. A huge number of clinics and pain services have undergone a decline in number of patient visits during COVID-19. Subsequently, most chronic pain facilities were deemed non-urgent, both outpatient and elective interventional procedures were limited or stopped during the COVID-19 pandemic to minimize risk of the viral spread. Patients with COVID-19 who are receiving opioids treatment can be more susceptible to respiratory depression and the absorption of fentanyl drug during transdermal administration such as fentanyl patch may increase with fever and could increase opioid side-effects. Whereas, patients who are prescribed transdermal opioids drugs shows the side effects such as sedation, nausea and vomiting, and respiratory depression. Thus, global topical pain relief market had a negative impact due to COVID-19.
Topical pain relief medications are applied directly to the epidermal layer of the skin at the area of inflammation or pain. Topical pain relief products are designed to relieve pain and utilize skin as the vehicle for drug administration and exert major action at the targeted site & in the central nervous system. These formulations are analgesic or anesthetic agents, which are applied on or around the painful site. The aim is to offer a slow and gradual release of pain relief medication into the bloodstream by keeping the blood levels relatively constant for a certain period of time. These medications offer lesser side effects as compared to oral medications. Topical pain relievers include the administration of non-opioids and opioids drugs. Non-opioids drugs include nonsteroidal anti-inflammatory drugs (NSAIDS), methyl salicylates, capsaicin, lidocaine, and other non-opioids. Opioids drugs include buprenorphine and fentanyl.
The growth of the global topical pain relief market is majorly driven by increase in prevalence of arthritis and other bone-related conditions, diabetic neuropathy, leading to pain. Other factors that boost the market growth include rise in adoption of topical pain relief products as they cause lesser side effects as compared to oral pain relief, upsurge in geriatric population across the world, and increase in demand for topical pain relief by sports players. However, factors such as topical pain relief medications can cause irritated skin and they have a strong odor or unpleasant smell that hamper the topical pain relief market growth. Conversely, the development of online platform for topical therapeutics is expected to provide lucrative growth opportunities for the market.
The World Health Organization (WHO) on January 30, 2020 declared COVID-19 outbreak a public health emergency of international concern. COVID-19 has affected around 210 countries across the globe.
Nationwide lockdown, government regulations, and continuous increase in infection rate across the country created a widespread financial impact on clinics and pain services. Large number of clinics and pain services has witnessed a drop in number of patient visits amid COVID-19 ultimately reducing client contact. Moreover, most chronic pain facilities were deemed non-urgent, both outpatient and elective interventional procedures were limited or stopped during the COVID-19 pandemic to minimize risk of the viral spread. Thus, a negative impact of COVID-19 on opioids topical pain relief market is observed.
The COVID-19 outbreak is anticipated to impact the growth of the global topical pain relief market. The COVID-19 pandemic has stressed healthcare systems of the world. A huge number of clinics and pain services have undergone a decline in number of patient visits during COVID-19.
Subsequently, most chronic pain facilities were deemed non-urgent, both outpatient and elective interventional procedures were limited or stopped during the COVID-19 pandemic to minimize risk of the viral spread. Patients with COVID-19 who are receiving opioids treatment can be more susceptible to respiratory depression and the absorption of fentanyl drug during transdermal administration such as fentanyl patch may increase with fever and could increase opioid side-effects. Whereas, patients who are prescribed transdermal opioids drugs shows the side effects such as sedation, nausea and vomiting, and respiratory depression. Thus, global topical pain relief market had a negative impact due to COVID-19.
The global topical pain relief market is segmented into therapeutic class, type, formulation, and distribution channel. On the basis of therapeutic class, the market is bifurcated into non-opioids and opioids. The non-opioids segment is further divided into nonsteroidal anti-inflammatory drugs (NSAIDS), methyl salicylate, capsaicin, lidocaine, and other non-opioids. The opioids segment is further bifurcated into buprenorphine and fentanyl. On the basis of type, the market is segmented into prescription pain relief and over-the-counter (OTC) relief. On the basis of formulation, the market is classified into cream, gel, spray, patch, and others. The distribution channels covered in the study include pharmacies & drug stores, e-commerce, and retail & grocery stores. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Presently, on the basis of therapeutic class, non-opioids segment is the major revenue contributor, and is projected to grow significantly during the forecast period due to its preferable use over the opioid drugs for treatment of mild to moderate pain. Due to less side effects as compared to opioids and no substance abuse, non-opioids are the preferred choice for the treatment of pain. However, due to restricted analgesic effects of the non-opioid drugs, their use is limited for the treatment of severe pain.
Increase in awareness regarding adverse effects of non-opioids, surge in number of geriatric populations, growth in number of patients with chronic pain, rise in prevalence of arthritis and other joint problems, majorly drive the growth of this segment. Arthritis is one of the most common and widely spread disorder that affects millions of people in the U.S. According to Centers for Disease Control and Prevention data, approximately 22.8% of total adult population was affected by arthritis in 2017.
According to distribution channel, the market is classified into pharmacies & drug stores, e-commerce, and retail & grocery stores. The e-commerce segment is anticipated to depict significant growth during the forecast period due to rise in preference for online purchase of drugs over the traditional methods, increase in awareness of online pharmacy, and rise in number of internet users.
The key players profiled in this report include Advacare Pharma, Glaxosmithkline Plc (GSK), Johnson & Johnson, Nestlé S.A., Novartis AG, Pfizer Inc., Reckitt Benckiser Group Plc., Sanofi, Sun Pharmaceutical Industries Ltd., and Topical Biomedics, Inc.
North America accounted for the majority of the global topical pain relief market share in 2019 and is anticipated remain dominant during the forecast period. This is attributed to the early approval of topical pain relief medications and high adoption of over-the-counter pain relief products in this region. Furthermore, the market in this region experiences growth due to the presence of majority of key players. Asia-Pacific is anticipated to witness lucrative growth, owing to increase in affordability, surge in healthcare expenditure, and rise in awareness toward safe pain relief products in this region.
Key Benefits For Stakeholders
Topical Pain Relief Market Report Highlights
| Aspects | Details |
|---|---|
| By THERAPEUTIC |
|
| By FORMULATION |
|
| By FORMULATION |
|
| By DISTRIBUTION CHANNEL |
|
| By Region |
|
| Key Market Players | SANOFI, NOVARTIS AG, RECKITT BENCKISER GROUP PLC, ADVACARE PHARMA, TOPICAL BIOMEDICS, INC, NESTLÉ S.A, SUN PHARMACEUTICAL INDUSTRIES LTD, GLAXOSMITHKLINE PLC (GSK), JOHNSON & JOHNSON, PFIZER INC |
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Top player positioning
3.4.Porter’s five force analysis
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in prevalence of arthritis
3.5.1.2.Growth in geriatric population
3.5.1.3.High demand for topical pain relief products by sportsperson
3.5.1.4.Lesser side effects caused by topical pain relief products as
compared to oral medicines
3.5.2.Restraints
3.5.2.1.Topical pain relief sometimes cause skin irritants
3.5.2.2.Topical pain relief is characterized by unpleasant odor
3.5.3.Opportunities
3.5.3.1.Emergence of online pharmacy
3.5.3.2.Opportunities in emerging economies
3.5.4.Impact analysis
3.6.COVID-19 Impact analysis on global topical pain relief market
CHAPTER 4:GLOBAL TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC
CLASS
4.1.Overview
4.1.1.Market size and forecast
4.2.Non-opioids
4.2.1.Key market trends, growth factors and opportunities
4.2.2.Market size and forecast, by type
4.2.3.Market size and forecast, by region
4.2.4.Market analysis, by country
4.2.4.1.Nonsteroidal anti-inflammatory drugs (NSAIDS)
4.2.4.2.Methyl salicylates
4.2.4.3.Capsaicin
4.2.4.4.Lidocaine
4.2.4.5.Other non-opioids
4.3.Opioids
4.3.1.Key market trends, growth factors and opportunities
4.3.2.Market size and forecast, by type
4.3.3.Market size and forecast, by region
4.3.4.Market analysis, by country
4.3.4.1.Buprenorphine
4.3.4.2.Fentanyl
CHAPTER 5:GLOBAL TOPICAL PAIN RELIEF MARKET, BY FORMULATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Cream
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Gel
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Spray
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Patch
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
5.6.Others
5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country
CHAPTER 6:GLOABL. TOPICAL PAIN RELIEF MARKET, BY TYPE
6.1.Overview
6.1.1.Market size and forecast
6.2.Prescription pain relief
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Over-the-counter pain relief
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
CHAPTER 7:GLOBAL TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL
7.1.Overview
7.1.1.Market size and forecast
7.2.Pharmacies & drug stores
7.2.1.Market size and forecast, by region
7.2.2.Market analysis, by country
7.3.E-Commerce
7.3.1.Market size and forecast, by region
7.3.2.Market analysis, by country
7.4.Retail & grocery stores
7.4.1.Market size and forecast, by region
7.4.2.Market analysis, by country
CHAPTER 8:TOPICAL PAIN RELIEF MARKET, BY REGION
8.1.Overview
8.1.1.Market size and forecast
8.2.North America
8.2.1.Key market trends, growth factors and opportunities
8.2.2.North America topical pain relief market, by country
8.2.2.1.U.S. topical pain relief market, by therapeutic class
8.2.2.2.U.S. topical pain relief market, by formulation
8.2.2.3.U.S. topical pain relief market, by type
8.2.2.4.U.S. topical pain relief market, by distribution channel
8.2.2.5.Canada topical pain relief market, by therapeutic class
8.2.2.6.Canada topical pain relief market, by formulation
8.2.2.7.Canada topical pain relief market, by type
8.2.2.8.Canada topical pain relief market, by distribution channel
8.2.2.9.Mexico topical pain relief market, by therapeutic class
8.2.2.10.Mexico topical pain relief market, by formulation
8.2.2.11.Mexico topical pain relief market, by type
8.2.2.12.Mexico topical pain relief market, by distribution channel
8.2.3.North America market size and forecast, by therapeutic class
8.2.4.North America market size and forecast, by formulation
8.2.5.North America market size and forecast, by type
8.2.6.North America market size and forecast, by distribution channel
8.3.Europe
8.3.1.Key market trends, growth factors and opportunities
8.3.2.Europe market size and forecast, by country
8.3.2.1.Germany topical pain relief market, by therapeutic class
8.3.2.2.Germany topical pain relief market, by formulation
8.3.2.3.Germany topical pain relief market, by type
8.3.2.4.Germany topical pain relief market, by distribution channel
8.3.2.5.France topical pain relief market, by therapeutic class
8.3.2.6.France topical pain relief market, by formulation
8.3.2.7.France topical pain relief market, by type
8.3.2.8.France topical pain relief market, by distribution channel
8.3.2.9.UK topical pain relief market, by therapeutic class
8.3.2.10.U.K. topical pain relief market, by formulation
8.3.2.11.UK topical pain relief market, by type
8.3.2.12.UK topical pain relief market, by distribution channel
8.3.2.13.Italy topical pain relief market, by therapeutic class
8.3.2.14.Italy topical pain relief market, by formulation
8.3.2.15.Italy topical pain relief market, by type
8.3.2.16.Italy topical pain relief market, by distribution channel
8.3.2.17.Spain topical pain relief market, by therapeutic class
8.3.2.18.Spain topical pain relief market, by formulation
8.3.2.19.Spain topical pain relief market, by type
8.3.2.20.Spain topical pain relief market, by distribution channel
8.3.2.21.Rest of Europe topical pain relief market, by therapeutic class
8.3.2.22.Rest of Europe topical pain relief market, by formulation
8.3.2.23.Rest of Europe topical pain relief market, by type
8.3.2.24.Rest of Europe topical pain relief market, by distribution channel
8.3.3.Europe market size and forecast, by therapeutic class
8.3.4.Europe market size and forecast, by formulation
8.3.5.Europe market size and forecast, by type
8.3.6.Europe market size and forecast, by distribution channel
8.4.Asia-Pacific
8.4.1.Key market trends, growth factors and opportunities
8.4.2.Asia-Pacific market size and forecast, by country
8.4.2.1.China topical pain relief market, by therapeutic class
8.4.2.2.China topical pain relief market, by formulation
8.4.2.3.China topical pain relief market, by type
8.4.2.4.China topical pain relief market, by distribution channel
8.4.2.5.Japan topical pain relief market, by therapeutic class
8.4.2.6.Japan topical pain relief market, by formulation
8.4.2.7.Japan topical pain relief market, by type
8.4.2.8.Japan topical pain relief market, by distribution channel
8.4.2.9.India topical pain relief market, by therapeutic class
8.4.2.10.India topical pain relief market, by formulation
8.4.2.11.India topical pain relief market, by type
8.4.2.12.India topical pain relief market, by distribution channel
8.4.2.13.Australia topical pain relief market, by therapeutic class
8.4.2.14.Australia topical pain relief market, by formulation
8.4.2.15.Australia topical pain relief market, by type
8.4.2.16.Australia topical pain relief market, by distribution channel
8.4.2.17.South Korea topical pain relief market, by therapeutic class
8.4.2.18.South Korea topical pain relief market, by formulation
8.4.2.19.South Korea topical pain relief market, by type
8.4.2.20.South Korea topical pain relief market, by distribution channel
8.4.2.21.Rest of Asia-Pacific topical pain relief market, by therapeutic class
8.4.2.22.Rest of Asia-Pacific topical pain relief market, by formulation
8.4.2.23.Rest of Asia- Pacific topical pain relief market, by type
8.4.2.24.Rest of Asia- Pacific topical pain relief market,
by distribution channel
8.4.3.Asia-Pacific market size and forecast, by therapeutic class
8.4.4.Asia-Pacific market size and forecast, by formulation
8.4.5.Asia-Pacific market size and forecast, by type
8.4.6.Asia-Pacific market size and forecast, by distribution channel
8.5.LAMEA
8.5.1.Key market trends, growth factors and opportunities
8.5.2.LAMEA market size and forecast, by country
8.5.2.1.Brazil topical pain relief market, by therapeutic class
8.5.2.2.Brazil topical pain relief market, by formulation
8.5.2.3.Brazil topical pain relief market, by type
8.5.2.4.Brazil topical pain relief market, by distribution channel
8.5.2.5.Saudi Arabia topical pain relief market, by therapeutic class
8.5.2.6.Saudi Arabia topical pain relief market, by formulation
8.5.2.7.Saudi Arabia topical pain relief market, by type
8.5.2.8.Saudi Arabia topical pain relief market, by distribution channel
8.5.2.9.South Africa topical pain relief market, by therapeutic class
8.5.2.10.South Africa topical pain relief market, by formulation
8.5.2.11.South Africa topical pain relief market, by type
8.5.2.12.South Africa topical pain relief market, by distribution channel
8.5.2.13.Rest of LAMEA topical pain relief market, by therapeutic class
8.5.2.14.Rest of LAMEA South Africa topical pain relief market, by formulation
8.5.2.15.Rest of LAMEA topical pain relief market, by type
8.5.2.16.Rest of LAMEA topical pain relief market, by distribution channel
8.5.3.LAMEA market size and forecast, by therapeutic class
8.5.4.LAMEA market size and forecast, by formulation
8.5.5.LAMEA market size and forecast, by type
8.5.6.LAMEA market size and forecast, by distribution channel
CHAPTER 9:COMPANY PROFILES
9.1.ADVACARE PHARMA
9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product Portfolio
9.2.GLAXOSMITHKLINE PLC (GSK)
9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Operating business segments
9.2.4.Product portfolio
9.2.5.Business performance
9.2.6.Key strategic moves and developments
9.3.JOHNSON & JOHNSON
9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Operating business segments
9.3.4.Product portfolio
9.3.5.Business performance
9.4.NESTLÉ S.A.
9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Operating business segments
9.4.4.Product Portfolio
9.4.5.Business performance
9.5.NOVARTIS AG
9.5.1.Company overview
9.5.2.Company snapshot
9.5.3.Operating business segments
9.5.4.Product portfolio
9.5.5.Business performance
9.6.PFIZER INC.
9.6.1.Company overview
9.6.2.Company snapshot
9.6.3.Operating business segments
9.6.4.Product portfolio
9.6.5.Business performance
9.7.RECKITT BENCKISER GROUP PLC
9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segments
9.7.4.Product Portfolio
9.7.5.Business performance
9.8.SANOFI
9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business segments
9.8.4.Product portfolio
9.8.5.Business performance
9.9.SUN PHARMACEUTICAL INDUSTRIES LTD.
9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product portfolio
9.9.5.Business performance
9.10.TOPICAL BIOMEDICS, INC.
9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product Portfolio
LIST OF TABLES
TABLE 01.GLOBAL TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 02.GLOBAL TOPICAL NON-OPIOIDS MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 03.TOPICAL NON-OPIOIDS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 04.GLOBAL TOPICAL OPIOIDS MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 05.TOPICAL OPIOIDS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 06.GLOBAL TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 07.TOPICAL PAIN RELIEF MARKET FOR CREAM, BY REGION, 2019–2027 ($MILLION)
TABLE 08.TOPICAL PAIN RELIEF MARKET FOR GEL, BY REGION, 2019–2027 ($MILLION)
TABLE 09.TOPICAL PAIN RELIEF MARKET FOR SPRAY, BY REGION, 2019–2027 ($MILLION)
TABLE 10.TOPICAL PAIN RELIEF MARKET FOR PATCH, BY REGION, 2019–2027 ($MILLION)
TABLE 11.TOPICAL PAIN RELIEF MARKET FOR OTHERS, BY REGION, 2019–2027 ($MILLION)
TABLE 12.GLOBAL TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 13.PRESCRIPTION TOPICAL PAIN RELIEF MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 14.OVER-THE-COUNTER TOPICAL PAIN RELIEF MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 15.GLOBAL TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 16.TOPICAL PAIN RELIEF MARKET FOR PHARMACIES & DRUG STORES, BY REGION,
2019–2027 ($MILLION)
TABLE 17.TOPICAL PAIN RELIEF MARKET FOR E-COMMERCE, BY REGION, 2019–2027 ($MILLION)
TABLE 18.GLOBAL TOPICAL PAIN RELIEF MARKET FOR REATIL & GROCERY SHOPS, BY REGION,
2017–2025 ($MILLION)
TABLE 19.GLOBAL TOPICAL PAIN RELIEF MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 20.NORTH AMERICA TOPICAL PAIN RELIEF MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 21.U.S. TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 22.U.S. TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 23.U.S. TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 24.U.S. TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 25.CANADA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 26.CANADA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 27.CANADA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 28.CANADA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 29.MEXICO TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 30.MEXICO TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 31.MEXICO TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 32.MEXICO TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 33.NORTH AMERICA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
TABLE 34.NORTH AMERICA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019-2027 ($MILLION)
TABLE 35.NORTH AMERICA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 36.NORTH AMERICA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 37.EUROPE TOPICAL PAIN RELIEF MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 38.GERMANY TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 39.GERMANY TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 40.GERMANY TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 41.GERMANY TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 42.FRANCE TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 43.FRANCE TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 44.FRANCE TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 45.FRANCE TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 46.UK TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 47.U.K. TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017–2027 ($MILLION)
TABLE 48.UK TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 49.UK TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 50.ITALY TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 51.ITALY TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 52.ITALY TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 53.ITALY TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 54.SPAIN TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 55.SPAIN TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 56.SPAIN TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 57.SPAIN TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 58.REST OF EUROPE TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 59.REST OF EUROPE TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 60.REST OF EUROPE TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 61.REST OF EUROPE TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL,
2019–2027 ($MILLION)
TABLE 62.EUROPE TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
TABLE 63.EUROPE TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019-2027 ($MILLION)
TABLE 64.EUROPE TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 65.EUROPE TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 66.ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 67.CHINA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 68.CHINA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 69.CHINA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 70.CHINA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 71.JAPAN TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 72.JAPAN TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 73.JAPAN TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 74.JAPAN TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 75.INDIA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 76.INDIA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 77.INDIA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 78.INDIA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 79.AUSTRALIA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 80.AUSTRALIA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 81.AUSTRALIA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 82.AUSTRALIA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 83.SOUTH KOREA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 84.SOUTH KOREA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 85.SOUTH KOREA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 86.SOUTH KOREA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 87.REST OF ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS,
2019–2027 ($MILLION)
TABLE 88.REST OF ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 89.REST OF ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 90.REST OF ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL,
2019–2027 ($MILLION)
TABLE 91.ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 92.ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019-2027 ($MILLION)
TABLE 93.ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 94.ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 95.LAMEA TOPICAL PAIN RELIEF MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 96.BRAZIL TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 97.BRAZIL TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 98.BRAZIL TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 99.BRAZIL TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 100.SAUDI ARABIA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 101.SAUDI ARABIA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 102.SAUDI ARABIA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 103.SAUDI ARABIA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 104.SOUTH AFRICA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 105.SOUTH AFRICA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 106.SOUTH ARICA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 107.SOUTH ARICA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 108.REST OF LAMEA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 109.REST OF LAMEA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 110.REST OF LAMEA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 111.REST OF LAMEA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 112.LAMEA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 113.LAMEA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019-2027 ($MILLION)
TABLE 114.LAMEA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 115.LAMEA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 116.ADVACARE: COMPANY SNAPSHOT
TABLE 117.ADVACARE: BUSINESS SEGMENTS
TABLE 118.ADVACARE: PRODUCT PORTFOLIO
TABLE 119.GSK: COMPANY SNAPSHOT
TABLE 120.GLAXOSMITHKLINE PLC.: OPERATING SEGMENT
TABLE 121.GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
TABLE 122.GSK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 123.J&J: COMPANY SNAPSHOT
TABLE 124.J&J: OPERATING SEGMENTS
TABLE 125.J&J: PRODUCT PORTFOLIO
TABLE 126.NESTLÉ: COMPANY SNAPSHOT
TABLE 127.NESTLÉ: OPERATING SEGMENTS
TABLE 128.NESTLÉ: PRODUCT PORTFOLIO
TABLE 129.NOVARTIS: COMPANY SNAPSHOT
TABLE 130.NOVARTIS: OPERATING SEGMENT
TABLE 131.NOVARTIS: PRODUCT PORTFOLIO
TABLE 132.PFIZER: COMPANY SNAPSHOT
TABLE 133.PFIZER: OPERATING SEGMENT
TABLE 134.PFIZER: PRODUCT PORTFOLIO
TABLE 135.RB: COMPANY SNAPSHOT
TABLE 136.RB: OPERATING SEGMENTS
TABLE 137.RB: PRODUCT PORTFOLIO
TABLE 138.SANOFI: COMPANY SNAPSHOT
TABLE 139.SANOFI: OPERATING SEGMENT
TABLE 140.SANOFI: PRODUCT PORTFOLIO
TABLE 141.SUN PHARMA: COMPANY SNAPSHOT
TABLE 142.SUN PHARMA: OPERATING SEGMENTS
TABLE 143.SUN PHARMA: PRODUCT PORTFOLIO
TABLE 144.TOPICAL BIOMEDICS: COMPANY SNAPSHOT
TABLE 145.TOPICAL BIOMEDICS: OPERATING SEGMENTS
TABLE 146.TOPICAL BIOMEDICS: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.GLOBAL TOPICAL PAIN RELIEF MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 04.HIGH BARGAINING POWER OF BUYERS
FIGURE 05.HIGH THREAT OF SUBSTITUTES
FIGURE 06.HIGH THREAT OF NEW ENTRANTS
FIGURE 07.MODERATE INTENSITY OF RIVALRY
FIGURE 08.IMPACT ANALYSIS: GLOBAL TOPICAL PAIN RELIEF MARKET
FIGURE 09.COMPARATIVE ANALYSIS OF TOPICAL NON-OPIOIDS MARKET, 2019 & 2027 ($MILLION)
FIGURE 10.NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET, 2019 & 2027 ($MILLION)
FIGURE 11.METHYL SALICYLATE MARKET, 2019 & 2027 ($MILLION)
FIGURE 12.CAPSAICIN MARKET, 2019 & 2027 ($MILLION)
FIGURE 13.LIDOCAINE MARKET, 2019 & 2027 ($MILLION)
FIGURE 14.OTHERS NON-OPIOIDS MARKET, 2019 & 2027 ($MILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF GLOBAL TOPICAL OPIOIDS MARKET, 2019 & 2027 ($MILLION)
FIGURE 16.BUPRENORPHINE MARKET, 2019 & 2027 ($MILLION)
FIGURE 17.FENTANYL MARKET, 2019 & 2027 ($MILLION)
FIGURE 18.COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR CREAM, 2019 & 2027 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR GEL, 2019 & 2027 ($MILLION)
FIGURE 20.COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR SPRAY, 2019 & 2027 ($MILLION)
FIGURE 21.COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR PATCH, 2019 & 2027 ($MILLION)
FIGURE 22.COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR OTHERS, 2019 & 2027 ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF PRESCRIPTION TOPICAL PAIN RELIEF MARKET, 2019 & 2027 ($MILLION)
FIGURE 24.COMPARATIVE ANALYSIS OF OVER-THE-COUNTER TOPICAL PAIN RELIEF MARKET,
2019 & 2027 ($MILLION)
FIGURE 25.COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR PHARMACIES & DRUG STORES,
2019 & 2027 ($MILLION)
FIGURE 26.COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR E-COMMERCE,
2019 & 2027 ($MILLION)
FIGURE 27.COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR REATIL & GROCERY SHOPS,
2019 & 2027 ($MILLION)
FIGURE 28.PERCENTAGE OF PEOPLE WITH DIFFERENT TYPES OF PAIN IN U.S., 2015
FIGURE 29.GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 30.GSK: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 31.GSK: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 32.J&J: NET SALES, 2017–2019 ($MILLION)
FIGURE 33.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 34.J&J: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 35.NESTLÉ: REVENUE, 2017–2019 ($MILLION)
FIGURE 36.NESTLÉ: REVENUE SHARE BY OPERATING SEGMENT, 2019 (%)
FIGURE 37.NESTLÉ.: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 38.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 39.NOVARTIS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 40.NOVARTIS: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 41.PFIZER: NET SALES, 2017–2019 ($MILLION)225
FIGURE 42.PFIZER: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 43.PFIZER: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 44.RB: REVENUE, 2017–2019 ($MILLION)
FIGURE 45.RB: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 46.RB: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 47.SANOFI.: NET SALES, 2017–2019 ($MILLION)
FIGURE 48.SANOFI: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 49.SANOFI: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 50.SUN PHARMA: NET SALES, 2017–2019 ($MILLION)
FIGURE 51.SUN PHARMA: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 52.SUN PHARMA: REVENUE SHARE BY REGION, 2019 (%)
According to analyst perspective, rise in number of patients suffering from bone pain conditions such as osteoarthritis and diabetic neuropathy, especially the geriatric population, is the major factor that drives the growth of the global topical pain relief market. Other factors such as rise in demand for pain relief products by sports persons, increase in geriatric population, easy availability of the drugs, higher healthcare awareness, and less side effects caused due to topical pain relief as compared to oral medications are expected to have a significant impact on the growth of the market. However, factors such as topical pain relief products cause irritated skin and are usually characterized by unpleasant odor, which is further expected to hamper the market growth.
Further the use of topical pain relief products is the highest in North America, owing to a large patient population and high adoption of over-the-counter based products, and is followed by Europe and Asia-Pacific. In addition, topical pain relief providers and distributors are focused on expanding their presence in the emerging economies, which in turn is anticipated to drive the market growth.
A. The total market value of topical pain relief market is $8864 million in 2019.
A. The forcast period for topical pain relief market is 2020 to 2027
A. The market value of topical pain relief market in 2027 is $12,219.7 million.
A. The base year is 2019 in topical pain relief market.
A. Glaxosmithkline Plc (GSK), Johnson & Johnson, Advacare Pharma held a high market postion owing to the strong geographical foothold in different regions.
A. Non-opioids segment is the major revenue contributor, and is projected to grow significantly during the forecast period. This is attributed to its preferable use over the opioid drugs for treatment of mild to moderate pain. However, it causes less side effects as compared to opioids and there is no substance abuse so, non-opioids are the preferred choice for the treatment of pain.
A. The major factor for the growth of topical pain relief market are increase in prevalence of arthritis and other bone-related conditions, diabetic neuropathy, leading to pain. Other factors that boost the market growth include rise in adoption of topical pain relief products as they cause lesser side effects as compared to oral pain relief, upsurge in geriatric population across the world, and increase in demand for topical pain relief by sports players.
A. Due to increase in affordability, surge in healthcare expenditure, and rise in awareness towards safe pain relief products in this region drive the global topical pain relief market.
A. Topical pain relief medications are applied directly to the epidermal layer of the skin at the area of inflammation or pain. Topical pain relief products are designed to relieve pain and utilize skin as the vehicle for drug administration and exert major action at the targeted site & in the central nervous system.
A. Topical pain relief medications are pain killers that are directly applied, rubbed, or sprayed on the skin over painful muscles or joints.
Start reading instantly.
This Report and over 66,804+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report